© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
A discussion series reviewing the differences between unbranded biologics and biosimilars and an overview of payer and provider considerations for decision-making.
September 30th 2022
With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.